Exercise of Camurus’ subscription warrant program 2018/2021
Lund, Sweden — 21 May 2021 — On 15 May 2021, the subscription period in Camurus AB’s (publ) (“Camurus”) subscription warrant program 2018/2021 started. In a first cashless exercise 260,782 shares, out of the program's total 607,565 shares, were subscribed for at a subscription price of SEK 133.40 per share. Through the exercise of the subscription warrants Camurus receives SEK 34,788,318.80.
A number of employees and senior executives of Camurus, including the company’s CEO and CFO, have participated. To finance the subscription of new shares and taxes related to the transaction, the senior executives have sold corresponding numbers of the newly subscribed shares. As a result of the transactions, the total shareholdings of the senior executives of Camurus have increased with 27,113 shares, corresponding to 1.5%.
The subscription period for the subscription warrant program 2018/2021 ends on 15 December 2021.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com
The information was submitted for publication on 21 May 2021 at 10:00 am CET.